2The long - Term Intervention with Pravastatin in lschaemic Disease(LIPID) Study Group. Prevention of cardiovascular tvents and death with Pravastatin in Patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349 - 1357.
4Kwiterovich P Hr. The antiatherogenic role of high - density lipoprotein cholesterol. Am J Cardiol 1998;892:13Q-21Q.
5Gorden T, Castelli WP, Hjortland Inc, et al. High density lipoprotein as a protective factor aqainst coronary heart desaese. Am J med 1977 ;62:707 - 714.
6M. J. chapman Atheroslerosis 2003; 171:1 - 13.
7Assmann G. et al. Am J cardiol 1996;77:1179-1184.
8Austin. Et al:JAMA 1988;260(13):1917- 1921.
9Franceschin: G. et al: Arterioscler Thromb 1994; 14:1969 -1575.
10Sander JR et al. Chrr Opin Endocrinol Diabetes 2002; 9: 312- 322.
2Reaven Gm. Role of inaulin resistance in human disease. Diabetes, 1988, 37:1595- 1607.
3Haffner SM. The insulin resistance syndrome revisited. Diabetes, 1996, 19:275 - 277.
4Kopelman PG, Albon L. Obesity. non - insulin - dependent diabetes mellitus and the metabolic syndrome. Br. Med Bull, 1997,53:322-340.
5World Health Organization: Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part I Diagnosis and classification of diabetes mellilus. Geneva, World Health Organization, 1999.
61999 World Health Organization. International Society of Hypertension Guidelines for the management of hypertension. Guidelines Subeommittee. J Hypertens, 1999, 17:151 - 183.
7World Hcalth Organization. Obesity. preventing and managing the global epidemic. WHO/NUT, 98, 1, Geneva: 1998.
